Compare EOG Resources Inc (EOG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Novartis AG — how do they compare? EOG Resources Inc trades at $138.18 (market cap $73.22B), while Novartis AG trades at $152.77 (market cap $287.66B). The key difference: Novartis AG is far larger — about 3.9× EOG Resources Inc's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| EOG | NVS | |
|---|---|---|
Market Cap | $73.22B | $287.66B |
Sector | Energy | Health |
52-Week High | $149.89 | $168.62 |
52-Week Low | $101.78 | $113.50 |
Enterprise Value | $77.68B | $327.68B |
Dividend Yield | 2.97% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $139.12, up 0.8% on the day, with a bullish technical outlook supported by moving averages and key resistance at $140. The company maintains strong profitability with a 23.39% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EOG's valuation discount and operational strength, with a consensus price target of $156.40 suggesting 12% upside.
EOG presents a compelling investment case with solid fundamentals, consistent earnings beats, and positive analyst sentiment, though risks include oil price volatility and elevated capital expenditures. The stock's current valuation below historical averages offers a margin of safety for long-term investors seeking exposure to a high-quality energy producer.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
